covid_cell_1_20

Pharmafile.com’s weekly COVID-19 news round-up

pharmafile | February 10, 2021 | News story | Research and Development COVID-19 

The past week has seen lots of positive COVID-19 vaccine news; Oxford University and AstraZeneca have announced development of another vaccine to tackle new COVID-19 mutations, an initial report has suggested that a longer interval between jabs will improve efficacy, and in South Korea a new treatment candidate from Celltrion has been granted marketing authorisation.

1. Longer Oxford-AstraZeneca vaccine interval improves efficacy, report says – Published 03/02/2021

A longer interval between doses of the Oxford University-AstraZeneca vaccine could substantially improve efficacy, according to a report published in the Lancet.

2. New Oxford University-AstraZeneca vaccine against COVID-19 mutations could be available by October – Published 05/02/21

Oxford University and AstraZeneca could release a new vaccine by October in order to counter the new mutations of COVID-19 that have arisen in the UK recently. 

3. South Korea approves Celltrion’s COVID-19 treatment Regdanvimab for emergency use – Published – 08/02/21

The South Korean Ministry of Food and Drug Safety (MFDS) has granted a conditional marketing authorisation (CMA) for the emergency use of Celltrion’s Regdanvimab (CT-P59), a monoclonal antibody COVID-19 treatment candidate.

4. CureVac enters collaboration with UK government on coronavirus variant vaccines– Published 08/02/21

CureVac has entered a collaboration with the UK government to develop and manufacture potential vaccine candidates against coronavirus variants, with the UK set to receive an initial supply of 50 million doses of any vaccines resulting from the partnership.

5. WHO backs AstraZeneca vaccine against South African variant – Published 09/02/21

World health officials have moved to ease concerns over the efficacy of the Oxford University-AstraZeneca vaccine against new variants of COVID-19.

Related Content

Gilead’s Veklury recommended by NICE for COVID-19 treatment

Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has …

NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19

The National Institute for Health and Care Excellence (NICE) has announced that it has expanded …

diana-polekhina-zbsthwt9vlc-unsplash_2

Moderna shares data from phase 1/2 trial for combination flu and COVID-19 vaccine

Moderna has announced positive interim results from the phase 1/2 trial of mRNA-1083, its investigational …

Latest content